A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
A Double-Blind Dose-Response Study Comparing Rapid Acting Intramuscular Olanzapine and Intramuscular Placebo in Agitated Patients With Schizophrenia
Sponsor: Eli Lilly and Company
Listed as NCT00316238, this PHASE2 trial focuses on Schizophrenia and remains completed. Sponsored by Eli Lilly and Company, it has been updated 5 times since 2006, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akita, Japan , Fukuoka, Japan , Fukushima, Japan , Gunma, Japan , Hiroshima, Japan , Hokkaido, Japan , Kagoshima, Japan , Kumamoto, Japan , Nagano, Japan , Okayama, Japan and 5 more locations